Login to Your Account

ArQule Makes Two Deals with Daiichi in Cancer

By Catherine Hollingsworth

Tuesday, November 11, 2008
ArQule would receive $75 million in up-front cash under two deals with Japan's Daiichi Sankyo Co. Ltd. - one to develop an anticancer compound and the other to discover a new generation of kinase inhibitors for cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription